Ampio pharmaceuticals receives approval to expand enrollment of its ap-019 phase ii study to india

Englewood, colo., june 15, 2021 /prnewswire/ -- ampio pharmaceuticals (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced it has received regulatory approval to expand enrollment of its ap-019 phase ii study to india.
AMPE Ratings Summary
AMPE Quant Ranking